Nachrichten und Videos - DYNAVAX TECHNOLOGIES - Englisch

Dynavax to Present at the 7th Annual Evercore HealthCONx Conference PR Newswire EMERYVILLE, Calif., Nov. 26, 2024 EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET . The presentation will be webcast and may be accessed...

Dynavax Announces $100 Million Accelerated Share Repurchase Program PR Newswire EMERYVILLE, Calif., Nov. 11, 2024 EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's...

Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates PR Newswire EMERYVILLE, Calif., Nov. 7, 2024 HEPLISAV-B ® quarterly net product revenue of $79.3 million , representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to...

Dynavax Announces $200 Million Share Repurchase Program PR Newswire EMERYVILLE, Calif., Nov. 7, 2024 EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock. The share repurchase program does not have an expiration date and Dynavax...

Dynavax Adopts Limited-Duration Stockholder Rights Plan PR Newswire EMERYVILLE, Calif., Oct. 29, 2024 EMERYVILLE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan"). The Dynavax Board adopted the Rights Plan in response to...

Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 PR Newswire EMERYVILLE, Calif., Oct. 24, 2024 EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024 , after the U.S. financial markets close. Dynavax will host a conference call...

Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates PR Newswire EMERYVILLE, Calif., Aug. 6, 2024 Achieved record quarterly HEPLISAV-B ® net product revenue of $70.2 million , growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE,...

Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif., July 23, 2024 EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024 , after the U.S. financial markets close. Dynavax will host a conference call and...

Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif., June 27, 2024 EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational...

Dynavax to Present at Upcoming Investor Conferences PR Newswire EMERYVILLE, Calif., May 28, 2024 EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44 th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT...

Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S. PR Newswire EMERYVILLE, Calif., May 14, 2024 EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis. The U.S....

Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire EMERYVILLE, Calif., May 8, 2024 HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Announces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles program Conference call today at 4:30 p.m. ET/ 1:30 p.m. PT...

Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 PR Newswire EMERYVILLE, Calif., April 24, 2024 EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024 , after the U.S. financial markets close. Dynavax will host a conference call and...

Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance PR Newswire EMERYVILLE, Calif., Feb. 22, 2024 HEPLISAV-B ® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expected to be $265 - $280 million Cash position increased to $742 million at year end and expect to be cash flow positive for full year 2024...

Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 PR Newswire EMERYVILLE, Calif., Feb. 8, 2024 EMERYVILLE, Calif. , Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024 , after the U.S. financial markets close....

Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights PR Newswire EMERYVILLE, Calif., Jan. 8, 2024 Preliminary full year 2023 HEPLISAV-B ® vaccine net product revenue of approximately $213 million , a 69% year-over-year increase Significant gains in HEPLISAV-B market share in key market segments, with total U.S. market share increasing to approximately 44% compared to approximately 35% at the end of 2022 Strengthened financial position with cash, cash...

Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire EMERYVILLE, Calif., Jan. 3, 2024 EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 11:15 a.m. PT . The presentation will be webcast and may be...

Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire EMERYVILLE, Calif., Nov. 20, 2023 EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET . The presentation will be webcast and may be...

Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance PR Newswire EMERYVILLE, Calif., Nov. 2, 2023 Generated quarterly HEPLISAV-B ® vaccine net product revenue of $62.3 million , a 66% year-over-year increase Raising full year HEPLISAV-B net product revenue guidance to $210 - $220 million , compared to prior range of $200 - $215 million Cash and investments increased to $720 million at quarter end; expects positive free cash flow for full year Conference...

Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 PR Newswire EMERYVILLE, Calif., Oct. 26, 2023 EMERYVILLE, Calif. , Oct. 26, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2023 financial results on Thursday, November 2, 2023 , after the U.S. financial markets close. Dynavax will host a conference call...